Skip to main content
Clinical Trials/NCT02510586
NCT02510586
Unknown
Not Applicable

Effect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya Disease

Seoul National University Hospital0 sites152 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Sevoflurane
Conditions
Hyperperfusion Syndrome
Sponsor
Seoul National University Hospital
Enrollment
152
Primary Endpoint
The incidence of postoperative cerebral hyperperfusion syndrome
Last Updated
10 years ago

Overview

Brief Summary

The aim of the present study is to evaluate the effect of sevoflurane postconditioning on the incidence of postoperative hyperperfusion syndrome following revascularization surgery in moyamoya patients.

Detailed Description

Postoperative hyperperfusion syndrome is a common complication in moyamoya disease patients receiving revascularization surgery. Previously its incidence has been reported to be 17\~50%, but little remains regarding frequency of reperfusion injury after revascularization surgery in patients with moyamoya disease. Volatile anesthetics such as sevoflurane has been introduced clinically to reduce reperfusion injury and preconditioning with sevoflurane induced ischemic tolerance like as ischemic preconditioning. However, there was no report on the neuroprotective effect of sevoflurane postconditioning on ischemic/reperfusion injury in human brain. Therefore, We evaluated the neuroprotective effect of sevoflurane postconditioning on the incidence of postoperative hyperperfusion syndrome after revascularization surgery in moyamoya disease patients.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
September 2018
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hee-Pyoung Park

Associate Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patients receiving cerebral revascularization surgery due to moyamoya disease

Exclusion Criteria

  • Patients who do not agree to the study
  • Patients with uncontrolled diabetes or hypertension
  • Patients using cyclooxygenase2 inhibitor or with previously using cyclooxygenase2 inhibitor
  • Patients with acute renal failure
  • Patients with previous intervention related with moyamoya disease

Arms & Interventions

Sevo_postconditioning

Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.

Intervention: Sevoflurane

Outcomes

Primary Outcomes

The incidence of postoperative cerebral hyperperfusion syndrome

Time Frame: postoperative day 15

Cerebral hyperperfusion syndrome was defined if all the following four criteria were met: i) new development of postoperative focal neurological deficits, ii) a delayed neurological deficits which were not shown in the immediate postoperative period; iii) postoperative reversible neurological deficits which were completely resolved within 15 days after operation; iii) neither definite haematomas nor definite acute infarction on a brain CT scan, on diffusion magnetic resonance imaging, or both.

Secondary Outcomes

  • The incidence of a new onset postoperative cerebral ischemia(participants will be followed for the duration of hospital stay, an expected average of 3 weeks.)
  • The incidence of a new onset postoperative brain hematoma(participants will be followed for the duration of hospital stay, an expected average of 3 weeks.)
  • The incidence of unrecovered neurological deficit(participants will be followed for the duration of hospital stay, an expected average of 3 weeks.)

Similar Trials